We found distinct mutational scenarios compared to single-site sequencing, characterized by high-frequency driver mutations in the ESCC population and a novel driver, PREX2, further verified by in vitro experiments. This evidence concerns the gene PREX2 and esophageal squamous cell carcinoma.